Heart failure & cardiomyopathies
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Primary result · ACM or first CVHResult — go to the resultHazard ratio 0.64 95% CI 0.50–0.83Authors' conclusion
In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH.
Study context
- Population
- Participants with transthyretin amyloid cardiomyopathy (ATTR-CM)611 (97%) analysed
- Participants
- 632 participants
- Comparison
- Acoramidis vs placebo
- Acoramidisn = 409
- Placebon = 202reference
- Primary endpoint
- Composite of:
- All-cause mortality
- First CV-related hospitalization
- Follow-up
- 30 months
Methodological detailsphase 3, double-blind, 2:1 randomisation
- Phase 3
- Double-blind
- 2:1 randomisation
Primary result
ACM or first CVH
Hazard ratio
0.64
95% CI 0.50–0.83
P = 0.0008
By group
Acoramidisvs Placebo
HR 0.64 (95% CI 0.50–0.83); P = 0.0008
As reported in the abstract
Further findings
| Outcome | Acoramidis | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| First CVH | 26.7% | 42.6% | 0.60 (0.45–0.80) | P = 0.0005 | |
| 0.512Hazard ratio (log scale) |
| Outcome | Acoramidis | Placebo | Relative risk ratio (95% CI) | P value |
|---|---|---|---|---|
| Annualized frequency of CVH | 0.22 | 0.45 | 50% (0.36–0.70) | P < 0.0001 |
All-cause mortality (ACM) or first CVH, by subgroup
- Efficacy consistent across subgroups
Original publication
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →